Crossmark

The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients – A Potential Paradigm Shift in Management

Published Online: 2020-05-14

Published Print: 2020-07

Authors

Spillane, Andrew J.

Menzies, Alexander M.

van Akkooi, Alexander C. J.
License Information

Text and Data Mining valid from 2020-05-14

Version of Record valid from 2020-05-14
More Information

Article History

Received: 5 February 2020

First Online: 14 May 2020

Disclosure

: AM: Advisory boards - BMS, MSD, Novartis, Roche, Pierre-Fabre; AvA: Advisory Board, Honoraria: Amgen, BMS, Novartis, MSD-Merck, Merck-Pfizer, 4SC; Research Grant: Amgen, BMS, Novartis; AJS reports no conflicts to disclose.

Document is current